SCHEMBL30748858

SCHEMBL30748858

Nc1ccc(OC2CC2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 2/20 0.41
RAB9A P51151 1/20 0.41
KEAP1 Q14145 1/20 0.40
ALDH1A1 P00352 1/20 0.40
BRCA1 P38398 1/20 0.40
HBB P68871 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LOX P28300 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
HRH3 Q9Y5N1 5/20 0.35
TDO2 P48775 1/20 0.35
ROCK1 Q13464 1/20 0.35
KCNH2 Q12809 2/20 0.35
GPR119 Q8TDV5 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748953 0.92 LOX (0.44) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL1749039 0.92 LOX (0.44) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL2228866 0.92 KDM4E (0.42) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL3651197 0.91 LOX (0.46) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL30748869 0.91 LOX (0.46) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL3396466 0.88 PIK3CA (0.41) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL5007629 0.88 ROCK1 (0.49) KDM4EMEN1KMT2APOLBRAB9A
SCHEMBL25204122 0.86 DGAT1 (0.50) KCNH2
SCHEMBL3690947 0.86 DGAT1 (0.50) KCNH2
SCHEMBL2816826 0.85 TDO2 (0.49) HRH3TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT KDM4E 2102/4885MEN1 301/4885KMT2A 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.